

Sara Labiano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3436300/publications.pdf>

Version: 2024-02-01

28
papers

2,207
citations

361413

20
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

4584
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. <i>Cancer Discovery</i> , 2016, 6, 71-79.	9.4	356
2	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). <i>Clinical Cancer Research</i> , 2016, 22, 3924-3936.	7.0	306
3	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. <i>Cancer Research</i> , 2016, 76, 5994-6005.	0.9	191
4	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 ^{-/-} /IL2R ³ null Immunodeficient Mice. <i>Cancer Research</i> , 2015, 75, 3466-3478.	0.9	137
5	Immune Response Regulation in the Tumor Microenvironment by Hypoxia. <i>Seminars in Oncology</i> , 2015, 42, 378-386.	2.2	121
6	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. <i>Current Opinion in Immunology</i> , 2014, 27, 89-97.	5.5	111
7	Deciphering CD137 (4-1BB) signaling in T cell costimulation for translation into successful cancer immunotherapy. <i>European Journal of Immunology</i> , 2016, 46, 513-522.	2.9	104
8	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. <i>Cancer Cell</i> , 2019, 36, 613-629.e7.	16.8	99
9	Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model. <i>Clinical Cancer Research</i> , 2013, 19, 6151-6162.	7.0	92
10	Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7551-7556.	7.1	92
11	Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. <i>Cancer Immunology Research</i> , 2015, 3, 449-454.	3.4	88
12	Tumor Resident Memory T Cells: New Players in Immune Surveillance and Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 2076.	4.8	76
13	Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation. <i>Cancer Immunology Research</i> , 2018, 6, 798-811.	3.4	62
14	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming. <i>Cancer Research</i> , 2018, 78, 6643-6654.	0.9	60
15	Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. <i>Oncolmmunology</i> , 2016, 5, e1062967.	4.6	52
16	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	1.1	48
17	CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes. <i>Cancer Immunology Research</i> , 2018, 6, 69-78.	3.4	34
18	Fibroblast Activation Protein β -Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021, 27, 4036-4053.	7.0	31

#	ARTICLE	IF	CITATIONS
19	CD69 is a direct HIF-1 α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes. <i>Oncolmmunology</i> , 2017, 6, e1283468.	4.6	27
20	Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 340.	4.8	27
21	CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4054-4065.	7.0	18
22	Cellular immunotherapies for cancer. <i>Oncolmmunology</i> , 2017, 6, e1306619.	4.6	17
23	Functional expression of CD137 (4-1BB) on T helper follicular cells. <i>Oncolmmunology</i> , 2015, 4, e1054597.	4.6	15
24	Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. <i>JCI Insight</i> , 2022, 7, .	5.0	14
25	Better Performance of CARs Deprived of the PD-1 Brake. <i>Clinical Cancer Research</i> , 2013, 19, 5546-5548.	7.0	11
26	LIF, a Novel STAT5-Regulated Gene, Is Aberrantly Expressed in Myeloproliferative Neoplasms. <i>Genes and Cancer</i> , 2011, 2, 593-596.	1.9	8
27	Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB). <i>Oncolmmunology</i> , 2018, 7, e1368605.	4.6	7
28	Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer. <i>Oncolmmunology</i> , 2014, 3, e27812.	4.6	3